Tsuguo Iwatani

Tsuguo Iwatani


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2007 in Genes to Cells
Verified
Journal Article
Open access
PDF file
RORyuichi Ohshima
Ryuichi Ohshima
TOTomohiko Ohta
Tomohiko Ohta
WWWenwen Wu
Wenwen Wu
AKAyaka Koike
Ayaka Koike
TITsuguo Iwatani
Tsuguo Iwatani
TOTakehito Otsubo
Takehito Otsubo
Adenomatous polyposis coli (APC), whose mutation causes colorectal cancers, is a key player in the Wnt signaling pathway. While the role of APC in inhibition of β‐catenin/LEF1‐dependent activation of transformation‐inducing genes has been intensively studied and well established, regulation of APC expression at the protein level is only partially understood. Here we report that APC is up‐regulated by EDD, the mammalian orthologue of Drosophila melanogaster“hyperplastic discs” gene (hyd) that is considered to be a putative tumor suppressor. Screening of APC immunocomplexes by mass spectrometry identified EDD as a putative APC‐interacting protein. Exogenously expressed and endogenous APC interacted with EDD in vivo. Indirect immunofluorescent analyses demonstrated that APC and EDD co‐localized in the cytoplasm of the cell. Over‐expression of EDD enhanced the protein expression level of APC and its binding partner Axin, resulting in inhibition of Wnt signaling downstream of β‐catenin. Conversely, siRNA knock‐down of EDD down‐regulated APC at the protein level without altering its mRNA level, causing enhanced protein expression of β‐catenin. Thus, through protein–protein interaction, EDD stabilizes APC and up‐regulates APC's function to inhibit β‐catenin, suggesting that EDD could act as a colorectal tumor suppressor.

10 April 2025 in Journal of Clinical Oncology
Verified
Journal Article
Open access
TYToshinari Yamashita
Toshinari Yamashita
SSShigehira Saji
Shigehira Saji
TTToshimi Takano
Toshimi Takano
YNYoichi Naito
Yoichi Naito
MTMichiko Tsuneizumi
Michiko Tsuneizumi
Norikazu MasudaNorikazu Masuda
Norikazu Masuda
PURPOSE: Trastuzumab-pertuzumab (HP) plus taxane is a current standard first-line therapy for recurrent or metastatic human epidermal growth factor 2 (HER2)+ breast cancer (BC). We investigated noninferiority of eribulin to a taxane when combined with dual HER2 blockade as first-line systemic treatment for locally advanced/metastatic HER2+ BC. METHODS: In the phase III EMERALD trial (target sample size, 480; ClinicalTrials.gov identifier: NCT03264547 /UMIN000027938), patients were randomly assigned (1:1) to receive eribulin 1.4 mg/m 2 once daily on days 1 and 8 (eribulin group) or a taxane (docetaxel 75 mg/m 2 once on day 1 or paclitaxel 80 mg/m 2 once daily on days 1, 8, and 15; taxane group) intravenously in a 21-day cycle, each with HP on day 1. The primary end point was progression-free survival (PFS; intention-to-treat population). Secondary end points included objective response rate, overall survival (OS), patient-reported quality of life (QoL), and safety. Noninferiority was tested using the stratified Cox proportional hazards model to estimate hazard ratios (HRs) for PFS events, with a noninferiority HR margin of 1.33. RESULTS: Between August 2017 and June 2021, 446 patients (median age, 56.0 years) were enrolled. The median PFS was 14.0 and 12.9 months in the eribulin group (n = 224) and taxane group (n = 222 [docetaxel/paclitaxel, n = 186/36]), respectively (HR, 0.95 [95% CI, 0.76 to 1.19]), which confirmed the noninferiority of the study regimen. The median OS was 65.3 months in the taxane group but has not been reached in the eribulin group. Median time to QoL deterioration was numerically longer with eribulin than with taxane. Adverse event (AE) rates were similar, despite the longer duration of eribulin use. Infusion reaction, skin-related AEs, diarrhea, and edema were more common with taxane, whereas neutropenia was more common with eribulin. CONCLUSION: The results suggested that eribulin + HP is an option for first-line treatment of locally advanced/metastatic HER2+ BC.

13 June 2023 in Breast Cancer
Verified
Journal Article
Open access
PDF file
SSSumito Saeki
Sumito Saeki
TITsuguo Iwatani
Tsuguo Iwatani
AKAtsuko Kitano
Atsuko Kitano
NSNaomi Sakurai
Naomi Sakurai
YTYuko Tanabe
Yuko Tanabe
CSCollaborative Study Group of Scientific Research of the Japanese Breast Cancer Society
Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society
Background: Financial toxicity (FT) is a notable concern for patients with breast cancer worldwide. The situation regarding FT in Japan, however, has not been well explored. This study examined FT in patients with breast cancer in Japan and presented an overview of the group study’s overall findings. Methods: The survey used the Questant application and primarily targeted patients with breast cancer attending research facilities and physicians who are members of the Japanese Breast Cancer Society. The Japanese version of the Comprehensive Score for FT (COST) was used to quantify patients’ FT. Multiple regression analysis was used to identify factors related to FT in patients with breast cancer in Japan and evaluate the sufficiency of information support level (ISL) for medical expenses. Results: We collected 1558 responses from patients and 825 from physicians. In terms of factors affecting FT, recent payments had the highest impact, followed by stage, and related departments positively affecting FT. Conversely, factors such as income, age, and family support were found to negatively affect FT. A significant discrepancy was identified between patients and physicians in perceived information support, with patients frequently feeling unsupported and physicians believing that they have provided adequate support. Furthermore, differences in the frequency of explanations and opportunities to ask questions about medical costs across FT grades were found. The analysis also showed that physicians with a better understanding of information support needs and greater knowledge of medical costs tended to provide more support that is comprehensive. Conclusion: This study emphasizes the importance of addressing FT in patients with breast cancer in Japan and highlights the need for enhanced information support, deeper understanding by physicians, and collaborative efforts among professionals to mitigate financial burden and provide personalized, tailored support for individual needs.

11 December 2022 in International Wound Journal
Verified
Journal Article
Open access
TITsuguo Iwatani
Tsuguo Iwatani
SSShinya Saito
Shinya Saito
Surgical site infections (SSIs) after thyroid surgery are rare complications, with incidence rates of 0.3%–1.6%. Using a Japanese database, we conducted exploratory analyses on the incidence of SSIs, investigated the incidence of SSIs by the National Nosocomial Infections Surveillance risk index, and identified the causative bacteria of SSIs. SSIs occurred in 50 (0.7%) of 7388 thyroid surgery cases. Risk index‐0 patients had the lowest incidence rate of SSIs (0.41%). The incidence of SSIs in risk index‐1 patients was 3.05 times the incidence of SSIs in risk index‐0 patients. The rate of SSI occurrence for risk index‐2 patients was 4.22 times the rate of SSI occurrence for risk index‐0 patients. Thirty‐one bacterial species were identified as the cause of SSIs in thyroid surgery cases, of which 12 (38.7%) SSIs were caused by Staphylococcus aureus and Staphylococcus epidermidis. Of the nine SSIs caused by Staphylococcus aureus, 55.6% (five cases) were attributed to methicillin‐resistant Staphylococcus aureus. Therefore, routine prophylactic antibiotic administration should be avoided, while the target for administration should be narrowed, according to the SSI risk. Administration of prophylactic antibiotics, such as 2 g piperacillin or 1 g cefazolin, is considered appropriate.

13 January 2021 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
TITsuguo Iwatani
Tsuguo Iwatani
FHFumikata Hara
Fumikata Hara
Tadahiko ShienTadahiko Shien
Tadahiko Shien
KSKeita Sasaki
Keita Sasaki
HKHiroshi Katayama
Hiroshi Katayama
HIHiroji Iwata
Hiroji Iwata
In April 2016, the Japanese government introduced health technology assessment as a response to rising medical expenses due to ‘medical innovation’. This study investigates how Japanese breast cancer patients who received treatment in Japan consider the financial value (willingness-to-pay; WTP) for their life and health by using the contingent valuation method (CVM) prospectively. First, 168 patients (84 primary breast cancer patients and 84 metastatic breast cancer patients) were pre-examined their WTP with dichotomous-choice method survey form. Next, 1,596 patients (798 primary breast cancer patients and 798 metastatic breast cancer patients) will be surveyed to their WTP for hypothetical scenarios in CVM. Based on our results, we will construct an evaluation axis from the patients’ viewpoint for the cost-effectiveness of clinical trials to establish standard treatments for breast cancer. We believe this research can contribute to create a meaningful healthcare system for patients, clinicians, industries, and healthcare policymakers.

23 August 2024 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Closed access
TITsuguo Iwatani
Tsuguo Iwatani
KSKeita Sasaki
Keita Sasaki
RMRyunosuke Machida
Ryunosuke Machida
Tadahiko ShienTadahiko Shien
Tadahiko Shien
FHFumikata Hara
Fumikata Hara
HIHiroji Iwata
Hiroji Iwata
Background: The increasing incidence and prevalence of breast cancer alongside diagnostic and treatment technology advances have produced a debate about the financial burden cancer places on the healthcare system and concerns about access. Methods: This study was conducted at 51 hospitals belonging to the Breast Cancer Study Group of the Japan Clinical Oncology Group using a web-based survey. The survey period conducted from July 2021 to June 2022. The study population included patients with metastatic breast cancer who received the related treatment as their first-line therapy. The proportion of patients who selected that regimen as their first-line treatment was tabulated. The total cost increase for each current standard therapy in comparison to conventional treatments was calculated. Results: A total of 702 patients (pts) were surveyed. Of those enrolled, 342 (48.7%) received high-cost treatment [estimated monthly drug costs exceeding ~500 000 Japanese Yen (JPY)]. Of these, 16 pts (4.7%) were receiving very high-cost treatment, amounting to more than 1 000 000 JPY per month. Fifty three (15.5%) of the patients who received high-cost treatment were 75 years of age or older. Of these, 1 pt (0.3%) were receiving very high-cost treatment. Analyses of incremental costs by current drugs showed that abemaciclib was costly with total additional cost of 6 365 670 JPY per patient. The total additional cost of the regimen per patient that included palbociclib was the second highest at 4011248 JPY, followed by atezolizumab at 3209033 JPY. Conclusions: The findings indicate that evaluating the financial implications of high-cost treatments requires considering not only drug prices but also analysis of total cost increase.